Pidotimod vs HBD-2
Head-to-head comparison of Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) and HBD-2 (Human Beta-Defensin 2) — benefits, dosing, side effects, research data, and where to buy.
| Property | Pidotimod | HBD-2 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid | Human Beta-Defensin 2 |
| Molecular Weight | 244.27 Da | 4316 Da |
| Half-Life | 3-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | 2 | 41 |
| Typical Dose | 400-800 mg/day | Research use only; no approved human dose |
| Route | Oral | Topical / Intranasal / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 200 | 420 |
| Research Status | Clinical | Pre-clinical |
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HBD-2 Benefits
- ✓broad-spectrum antimicrobial activity
- ✓epithelial barrier defense
- ✓innate immune modulation
- ✓anti-biofilm potential
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HBD-2 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
HBD-2 Side Effects
- ⚠local irritation at high concentrations
- ⚠proteolytic instability
- ⚠potential pro-inflammatory signaling
Research Overview
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
HBD-2
Human beta-defensin 2 has been studied extensively for direct microbicidal effects and for its role in shaping mucosal immunity. Preclinical work shows activity against Gram-negative and Gram-positive organisms, with additional effects on leukocyte recruitment and wound defense.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.